INCB-000928

CAS No. 2173389-57-4

INCB-000928( —— )

Catalog No. M37084 CAS No. 2173389-57-4

Zilurgisertib (INCB-000928) is a selective and potent ALK 2 inhibitor for the study of cancer and MF anemia.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 324 Get Quote
5MG 511 Get Quote
10MG 825 Get Quote
25MG 1546 Get Quote
50MG 2530 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    INCB-000928
  • Note
    Research use only, not for human use.
  • Brief Description
    Zilurgisertib (INCB-000928) is a selective and potent ALK 2 inhibitor for the study of cancer and MF anemia.
  • Description
    Zilurgisertib (INCB-000928; NBU-928) is a selective ALK 2 inhibitor for researching diseases such as cancer.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    ALK
  • Recptor
    ALK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2173389-57-4
  • Formula Weight
    502.65
  • Molecular Formula
    C30H38N4O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (198.95 mM; Ultrasonic )
  • SMILES
    [H][C@]12C[C@]1(CN(C2)C1CCOCC1)c1ccc(cc1)-c1cnc(N)c(c1)C(=O)NC12CCC(O)(CC1)CC2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Li J, et al. Preparation of aminopyridine derivatives and their use as selective ALK-2 inhibitors. WO2018014829 A1.
molnova catalog
related products
  • Tyrphostin AG 879

    Tyrphostin AG 879 effectively inhibits HER2/ErbB2 (IC50: 1 μM), 100- and 500-fold higher selective to ErbB2 than EGFR and PDGFR.

  • SB-505124 hydrochlor...

    SB-505124 hydrochloride (SB505124 hydrochloride) is an orally available, selective and potent inhibitor of TGF-β type I receptors (ALK4, ALK5, ALK7) with IC50 values of 129 nM and 47 nM for ALK4 and ALK5, respectively.

  • Ascrinvacumab

    Ascrinvacumab (PF-03446962) is a highly humanized IgG2 monoclonal antibody against ALK-1 with a Kd value of 7 nM for human ALK1.